Is AbbVie Stock a Buy Now?
AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...
Managed Healthcare Executive3d
Health of the Biosimilars Industry, Getting Rid of Clinical Trials, PBMs As Obstacles and Other Biosimilar Topics | Q&A With Craig Burton, MBA
We spoke recently with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the ...
centerforbiosimilars2d
Psoriasis Biosimilars Saved VA $67 Million in 2023
The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...
Managed Healthcare Executive2d
The Power of PBMs and Biosimilars, 2025 Launches of the Stelara Biosimilars, the IRA and Interchangeability | Q&A with Craig Burton, MBA
The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...
$22.68 Bn Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
centerforbiosimilars4d
Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential
Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...
Alvotech initiated with a Buy at UBS
UBS initiated coverage of Alvotech (ALVO) with a Buy rating and $18 price target Alvotech is a pure-play biosimilar company, with a ...